DIVI'S LABORATORIES LTD.

Divis Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives. The window will be shut from July 01, 2026, and will reopen 48 hours after the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. The exact date of the board meeting to approve these results will be communicated later. This measure is in accordance with the company's internal code of conduct for insider trading.

Divi's Laboratories Limited's Board of Directors has recommended a dividend of ₹30 per fully paid-up Equity Share (1,500%) for the Financial Year ended March 31, 2026. This dividend, if approved by shareholders at the 36th AGM on August 10, 2026, will be distributed on or after August 14, 2026. The record date for eligibility is July 24, 2026. The company has also communicated details regarding Tax Deducted at Source (TDS) on dividends to shareholders, outlining rates and documentation requirements for exemption or lower deduction for both resident and non-resident shareholders.

Divis Laboratories Ltd's board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹30 (1,500%) per equity share of face value ₹2 for FY26, subject to shareholder approval at the AGM on August 10, 2026; record date is July 24, 2026. Standalone revenue from operations stood at ₹2793 Cr for the quarter ended March 31, 2026, and ₹10388 Cr for the year ended March 31, 2026. The Board meeting concluded at 11.50 Hrs.

The Board of Directors of Divis Laboratories Ltd, in its meeting on May 23, 2026, recommended a dividend of ₹30 per share (1500%) subject to shareholder approval at the upcoming Annual General Meeting. The 36th AGM is scheduled for August 10, 2026, with a record date of July 24, 2026, for dividend payment eligibility. The board also approved the audited financial results for the quarter and year ended March 31, 2026.

Divis Laboratories Ltd's board approved the audited financial results for the quarter and year ended March 31, 2026. The company reported revenue from operations of ₹10,894 Cr and a profit after tax of ₹2,607 Cr for FY26. A final dividend of ₹30 (1,500%) per equity share has been recommended, subject to shareholder approval at the AGM on August 10, 2026. The record date for the dividend is July 24, 2026.

Divis Laboratories Ltd has scheduled a Board of Directors meeting on May 23, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a dividend on equity shares for the financial year 2025-26. The trading window, which has been closed since April 1, 2026, will remain closed until May 25, 2026, 48 hours after the declaration of the financial results.

Divis Laboratories Ltd has announced the closure of the trading window from April 01, 2026 till 48 hours after the declaration of audited financial results for the quarter and financial year ended March 31, 2026. This decision is in accordance with the Company’s Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons, Immediate Relatives of Designated Persons and Insiders. The date of the Board meeting for the declaration of the audited financial results will be intimated in due course.

Divis Laboratories Ltd. has received a Draft Order under Section 144C(1) of the Income Tax Act, 1961 from the Assistant Commissioner of Income Tax, Central Circle-2(1), Hyderabad. The order pertains to the FY2022-23 (Assessment year 2023-24) and proposes certain additions/disallowances amounting to Rs.570.51 crores. The additions are on account of Transfer Pricing adjustments on specified domestic transactions and corporate tax adjustments. The Company is evaluating the Draft Order and plans to file an appeal against the same within the stipulated time. As per the Draft Order, penalty proceedings u/s.270A of the Income Tax Act, 1961 will be initiated separately for alleged under reporting of income in respect of the above addition.

Divis Laboratories Ltd. has announced the financial results for the quarter and nine months ended December 31, 2025, at its board meeting on February 11, 2026. The company reported a profit before tax of Rs. 26 crores for the quarter and Rs. 6 crores for the nine-month period.

Divis Laboratories Ltd has announced that its Board of Directors will meet on February 11, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The trading window for dealing in securities of the company will remain closed from January 01, 2026, to February 13, 2026, as per the earlier announcement.